Current news and events

New Nature Genetics paper from Tekpli's group:Why do some breast cancers respond to hormone therapy while others do not?

Co-first authors flanked by co-senior authors
Co-first authors flanked by co-senior authors

In a study published on 4 November in Nature Genetics, Ilayda Altinönder and Villads Winton from Xavier Tekpli’s group, together with Jürgen Geisler, Senior Consultant in Medical Oncology at Ahus, and their co-authors identified biological differences between breast tumors that respond well to aromatase inhibitors and those that do not. 

Through longitudinal single-cell analyses of breast tumors, the authors found that tumors responding well to treatment were strongly associated with estrogen signaling, the pathway targeted by aromatase inhibitors.
Sensitivity to treatment was associated with a more active anti-tumor immune environment, including T cells and B cells that expanded and remained active during treatment.

Fátima Carneiro receives the first Jan Vincents Johannessen Award

Portuguese pathologist Fátima Carneiro has been awarded the new Jan Vincents Johannessen Award “Fire in your heart” for outstanding research and promotion of onco-pathology. The award was presented at the Onco-Pathology Meeting in Oslo on 5 November.

The Jan Vincents Johannessen Award “Fire in your heart” is a new award recognizing outstanding onco-pathology research, the modernization of pathology, and leadership in the field. It is given to an exceptional pathologist in molecular cancer diagnostics who has demonstrated outstanding research, leadership and implementation that has reshaped onco-pathology. The award consists of a hand-made glass work of art and a personal prize of €20,000.

Open Day - Tuesday, November 10, 2026LVB Imaging Centre in Life Science Building

Meet our imaging specialists, explore our advanced microscopy technologies, and learn how our expertise and services can support your research. Drop by for a tour, ask questions, and discuss your imaging needs with our team.
Time: Tuesday November 10, 12:00-15:00
Place: Life Science Building, 2nd Floor - East tower

Open flyer (PDF)

Link collection - current news:News stories involving OUS researchers

Changes to the Norwegian Health Research Act 

On 1 November 2026, the revised Norwegian Health Research Act entered into force. The amendments clarify that research institutions are responsible for ensuring that health research projects comply with applicable legal requirements.

Under the revised legislation, research-responsible managers and principal investigators must ensure that relevant legal compliance assessments are conducted before a project begins, throughout its lifecycle, and when it is completed.

These requirements emphasize the institutions’ responsibility for maintaining legal compliance and proper governance of health research projects.

Lynch Norge patient association officially registered:A new voice for people with Lynch syndrome

Many people in Norway with Lynch syndrome - a hereditary condition that carries a high risk of developing cancer -have long felt the need for an organization of their own to represent them. Lynch Norge has now been established to address this need. This is a direct result of PREDI-LYNCH, a research and innovation project aiming to determine whether blood tests, combined with risk models based on artificial intelligence, can help prevent cancer in individuals with Lynch syndrome. PREDI-LYNCH is funded through the EU’s Cancer Mission under the Horizon Europe programme, involving 16 different countries, including Norway.
Mev Dominguez-Valentin, leader of the Inherited and Familial Cancer research group at the Department of Tumor Biology at the Institute for Cancer Research, is the coordinator of PREDI-LYNCH.

New study identifies patients who benefit most from carboplatin treatment in aggressive breast cancer

Olav Engebråten
Olav Engebråten

Researchers at Oslo University Hospital and the University of Oslo have published results from the I-BCT-1 clinical trial (PI Prof. Olav Engebraaten) in Clinical Cancer Research, demonstrating a long-term benefit of adding carboplatin to neoadjuvant chemotherapy for patients with triple-negative breast cancer.

The study was initiated in 2014 to investigate whether adding carboplatin to standard chemotherapy could improve outcomes for patients with aggressive breast cancer. Among patients with triple-negative breast cancer, only 9% of those receiving carboplatin experienced disease recurrence, compared with 30% of patients treated with standard therapy alone. Such treatment approach recently became part of standard clinical care for this patient group. 

InteRSurg Research Conference 2026:Research that makes a difference for children and families

What can contribute to better treatment, less pain, and improved follow-up care for children and families? This was a recurring theme as healthcare professionals, researchers, and students gathered for this year’s InteRSurg Research Conference at Oslo University Hospital.

The conference brought together nurses, physicians, researchers, and students from across the Nordic region for a day of professional learning, knowledge sharing, and engaging discussions across disciplines and professions.

Tom Hemming Karlsen, Head of Research in the Division of Surgery and Specialized Medicine, at Oslo University Hospital, opened the conference by highlighting the importance of strong research environments and interprofessional collaboration.

Press release:Landmark global initiative sets out roadmap for equitable precision oncology

Kjetil Taskén and Live Fagereng
Kjetil Taskén and Live Fagereng

A commission report on precision medicine in cancer was published in "Lancet Oncology" on September 25. Kjetil Taskén is the only Norwegian author involved in this work, and OUS is listed as a contributing institution. In conjunction with this project, Taskén was invited to write a review article on the status of cancer genomics and precision oncology in Europe. He led this work, together with Live Fagereng from OUS (first author), alongside 25 other principal authors from various European countries and 159 consortium authors - a broad collaboration designed to capture the full scope of the initiative across Europe. The resulting article was published in "The Lancet Regional Health – Europe" simultaneously with the "Lancet Oncology" report.  This European status overview is one of several papers being released alongside the commision report; the aim is to provide a comprehensive worldwide picture of the situation. The publication is scheduled to coincide with the UICC World Cancer Congress in Hong Kong on September 25, aligning with the release of the Lancet Oncology report and other Lancet journal publications.

More news from the archive